Radiaction Medical, an Israeli medical device company specializing in radiation protection in the areas of interventional cardiology and electrophysiology, announced that it has closed a $10 million financing round and has also received approval for the FDA for marketing its Shield system in the United States.
InnovaHealth Partners led the funding round, the proceeds of which will be used to launch Radiaction’s Shield system in the United States and further commercialize it in Europe.
People working in cath labs (“catheter labs”) are exposed to high levels of scattered radiation generated by the use of x-ray fluoroscopy. Medical teams wear heavy lead aprons for protection, but their head, arms, and legs are unprotected, leading to an increased risk of brain tumors, cognitive impairment, and other radiation-related illnesses. Additionally, heavy lead aprons can cause serious orthopedic injuries. A significant part of the radiation is dispersed throughout the catheterization laboratory by its interaction with the patient’s body and the x-ray table. Mounted directly to the headband, Radiaction’s shielding system blocks and captures scattered radiation at the source. According to the company, clinical studies demonstrate that the device reduces radiation throughout the cath lab by more than 90%, with even higher reduction rates for the head and upper body of all personnel present. in the room.
“We are very pleased with the FDA clearance for our device and look forward to protecting physicians and medical personnel performing interventional procedures in the United States,” said Jonathan Yifat, CEO of Radiaction. “This funding will boost our commercialization in the United States and Europe, and allow us to strengthen our team and our presence in the market.”
The company was founded by serial entrepreneur Amir Belson in 2014, whose previous ventures include medical device startup Vascular Pathways Inc. acquired by New Jersey-based medical device company CR Bard Inc. for 81, $5 million in 2015.